.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Cantor Fitzgerald
Fuji
Moodys
US Army
AstraZeneca
Chubb
QuintilesIMS
Chinese Patent Office

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,521,423

« Back to Dashboard

Which drugs does patent 7,521,423 protect, and when does it expire?


Patent 7,521,423 protects BYETTA and is included in one NDA. There has been one Paragraph IV challenge on Byetta.

This patent has seventy-five patent family members in seventeen countries.

Summary for Patent: 7,521,423

Title:Exendin pharmaceutical compositions
Abstract:Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.
Inventor(s): Young; Andrew A. (La Jolla, CA), Gedulin; Bronislava (Del Mar, CA)
Assignee: Amylin Pharmaceuticals, Inc. (San Diego, CA)
Application Number:10/896,244
Patent Claim Types:
see list of patent claims
Composition; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca AbBYETTAexenatide syntheticINJECTABLE;SUBCUTANEOUS021773-001Apr 28, 2005RXYesYes► Subscribe► Subscribe► SubscribeY
Astrazeneca AbBYETTAexenatide syntheticINJECTABLE;SUBCUTANEOUS021773-002Apr 28, 2005RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,521,423

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,288,338Exendin and exendin agonists for eating disorders► Subscribe
7,220,721Exendin agonist peptides► Subscribe
8,026,210Exendins and exendin agonist analogs to regulate gastrointestinal motility► Subscribe
7,700,549Exendin agonist analogs to treat diabetes► Subscribe
6,858,576 Methods for regulating gastrointestinal motility► Subscribe
7,223,725Exendin agonist compounds► Subscribe
7,741,269Exendins and exendin agonists for weight reduction and obesity► Subscribe
7,297,761Pharmaceutical compositions containing exendins► Subscribe
7,157,555Exendin agonist compounds► Subscribe
7,115,569Exendins, exendin agonists, and methods for their use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,521,423

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office1032587► Subscribe
European Patent Office1066314► Subscribe
European Patent Office1629849► Subscribe
European Patent Office1938830► Subscribe
European Patent Office1938831► Subscribe
European Patent Office1941900► Subscribe
European Patent Office2016950► Subscribe
Spain2247676► Subscribe
Spain2293688► Subscribe
Spain2294822► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
Harvard Business School
McKesson
Fish and Richardson
Covington
Accenture
Cantor Fitzgerald
Chinese Patent Office
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot